According to a new report, published by KBV research, The Global Antacids Market size is expected to reach $7.9 billion by 2029, rising at a market growth of 3.2% CAGR during the forecast period.
The Liquids segment is showcasing a CAGR of 3.6% during (2023 - 2029). Since they are simple to use, convenient, and quick to swallow, liquid antacids are getting increasingly well-liked for use while traveling. Additionally, a variety of flavors are readily available, making liquid antacids very tasty for customers of all ages. Furthermore, elderly patients and children who may have trouble swallowing capsules or tablets frequently prefer liquid antacids. Therefore, the liquid antacid segment is anticipated to increase at a steady rate because of this tendency.
The Non-systemic segment acquired maximum revenue share in the Global Antacids Market by Mechanism of Action in 2022 thereby, achieving a market value of $5.5 billion by 2029. These types of antacids do not cause the production of systemic alkalosis as well as are not absorbed. The market's abundance of non-systemic antacid products, including chewable tablets, effervescent tablets, and liquids, is credited with the high demand as well as a rise in public knowledge of the benefits of non-systemic antacids. The non-systemic antacid group is expected to increase more rapidly as a result.
The Online Pharmacies segment has shown the growth rate of 4% during (2023 - 2029). Due to the rise in prominence of e-commerce websites as well as online drug shopping, it is predicted that the online providers' segment will expand rapidly. The ease of online shopping, in addition to the doorstep delivery services and significant discounts provided by these websites, is anticipated to fuel the growth of the segment.
The North America market dominated the Global Antacids Market by Region in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $2.9 billion by 2029. The Asia Pacific market is poised to grow at a CAGR of 3.9% during (2023 - 2029). Additionally, The Europe market would witness a CAGR of 3% during (2023 - 2029).
Full Report: https://www.kbvresearch.com/antacids-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Alkem Laboratories Ltd., Bayer AG, Cipla Limited, Pfizer, Inc., Prestige Consumer Healthcare, Inc., Reckitt Benckiser Group PLC, WellSpring Pharmaceutical Corporation (Avista Capital Partners), Sanofi S.A. and Sun Pharmaceutical Industries Ltd.
By Formulation Type
By Mechanism of Action
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
